ReviewAbdominal radiology (New York)2020
Hematologic malignancies of the gastrointestinal luminal tract.
Review in Abdominal radiology (New York), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Heterogeneity in primary gastrointestinal DLBCL: from clinical management to molecular mechanisms and treatment strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- The risk of digestive tract complications in patients with gastrointestinal lymphoma: a propensity score study.BMC gastroenterology · 2026Article
- Clinical Characteristics and Independent Risk Factors of Primary Gastrointestinal Lymphoma Complicated with Gastrointestinal Complications.International journal of general medicine · 2026Article
- Rare Presentation of Gastric Myeloid Sarcoma.ACG case reports journal · 2026Article
- Primary Gastrointestinal B-Cell Lymphomas: A Clinicopathological Review.Journal of hematology · 2025Review
- Comparison of clinical features of patients with or without severe gastrointestinal complications in aggressive gastrointestinal lymphomas.World journal of gastrointestinal oncology · 2024Article
- Rapid progression from MDS to AML with gastric submucosal tumour as an extramedullary infiltration.BMJ case reports · 2024Article
- The causality between gut microbiota and non-Hodgkin lymphoma: a two-sample bidirectional Mendelian randomization study.Frontiers in microbiology · 2024Article
- Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs.Frontiers in oncology · 2024Article
- B Cell Lymphomas of the GI Tract.Current gastroenterology reports · 2021Review
- Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematologic malignancies include several lymphoproliferative and myeloproliferative disorders, many of which are frequently encountered in current health care settings. These malignancies frequently affect the gastrointestinal (GI) tract, either by secondary extranodal or extramedullary extension to the GI tract, or as a primary process arising in the GI tract. In fact, the GI tract may represent the most common extranodal site of involvement in many of them, such as lymphoma. Furthermore, in the current era of improved cancer treatment and advanced transplant procedures with increased survival, it has been quite common to encounter GI involvement by these malignancies through the disease course. Post-transplant lymphoproliferative disorder following kidney transplantation, for example, very commonly involves the GI tract. Other conditions that can involve the GI tract include multiple myeloma, plasmacytoma, myeloid sarcoma, mastocytosis, and Castleman disease. Imaging diagnosis of these malignancies can be challenging, since they are much less common than primary GI cancers and both share many common imaging features as well. However, certain imaging features, particularly in combination with a matching clinical scenario, play a pivotal role in diagnosing these conditions and directing further evaluation. In this article, we review common and rare hematologic malignancies of the GI tract and discuss their pathophysiologic, clinical, and imaging features.
Indexed as
Identifiers
31707438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.